Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of obesity on inflammatory cytokines and 90- and 180-day survival in patients with alcohol-associated hepatitis.

Clinical and translational gastroenterology·2026
Same author

Sparse CCA-Based Mediation Analysis with High-Dimensional Exposures and Mediators.

Bioinformatics (Oxford, England)·2026
Same author

Application of Artificial Intelligence for Detection of Dental Carious Lesions in Digital Dental Radiographs: An <i>In Vitro</i> Study.

International journal of clinical pediatric dentistry·2026
Same author

Mean Arterial Pressure at Admission Predicts 28-day Mortality in Patients with Severe Alcohol-associated Hepatitis.

Clinical and translational gastroenterology·2026
Same author

Extended precision cut liver slice culture models liver regeneration and ductular reaction.

eGastroenterology·2026
Same author

EASL position paper on preclinical models of steatotic liver disease.

Journal of hepatology·2026

Related Experiment Video

Updated: May 11, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

MicroRNAs in liver disease.

Gyongyi Szabo1, Shashi Bala

  • 1Department of Medicine, University of Massachusetts Medical School, LRB208, 364 Plantation Street, Worcester, MA 01605, USA.

Nature Reviews. Gastroenterology & Hepatology
|May 22, 2013
PubMed
Summary

MicroRNAs (miRNAs) are key regulators of liver function and disease. This review highlights their roles in liver inflammation, fibrosis, and cancer, and their potential as therapeutic targets and biomarkers.

Area of Science:

  • Hepatology and molecular biology
  • Focus on microRNA (miRNA) research in liver diseases

Background:

  • MicroRNAs (miRNAs) are small, noncoding RNAs regulating gene expression.
  • Increasing evidence implicates miRNAs in the pathogenesis of various liver diseases.
  • MicroRNA-122 is abundant in hepatocytes and plays a role in Hepatitis C Virus (HCV) replication.

Purpose of the Study:

  • To review current advancements in understanding miRNAs in liver diseases, inflammation, and cirrhosis.
  • To discuss the therapeutic potential and biomarker utility of miRNAs in hepatology.

Main Methods:

  • Literature review of studies on miRNAs in liver pathology.
  • Analysis of miRNA roles in viral hepatitis, alcohol-related liver disease, metabolic syndrome, autoimmune liver conditions, fibrosis, and hepatocellular carcinoma.

More Related Videos

Quantitative Real-Time Polymerase Chain Reaction Evaluation of MicroRNA Expression in Kidney and Serum of Mice with Age-Dependent Renal Impairment
06:48

Quantitative Real-Time Polymerase Chain Reaction Evaluation of MicroRNA Expression in Kidney and Serum of Mice with Age-Dependent Renal Impairment

Published on: April 29, 2022

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Related Experiment Videos

Last Updated: May 11, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Quantitative Real-Time Polymerase Chain Reaction Evaluation of MicroRNA Expression in Kidney and Serum of Mice with Age-Dependent Renal Impairment
06:48

Quantitative Real-Time Polymerase Chain Reaction Evaluation of MicroRNA Expression in Kidney and Serum of Mice with Age-Dependent Renal Impairment

Published on: April 29, 2022

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

Main Results:

  • MicroRNA-122 is a validated therapeutic target for HCV and is implicated in other liver diseases.
  • Numerous other miRNAs are involved in liver inflammation and fibrosis development.
  • Circulating miRNAs show promise as biomarkers for liver damage and hepatocellular carcinoma progression.

Conclusions:

  • miRNAs are crucial regulators of liver function and disease.
  • miRNA modulation offers a promising future therapeutic strategy for liver diseases.
  • Circulating miRNAs represent valuable biomarkers for early disease detection and monitoring.